New Edge Advisors, LLC Gain Therapeutics, Inc. Transaction History
New Edge Advisors, LLC
- $16.2 Billion
- Q1 2025
A detailed history of New Edge Advisors, LLC transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 10,600 shares of GANX stock, worth $16,748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,600Holding current value
$16,748% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding GANX
# of Institutions
38Shares Held
3.53MCall Options Held
8.4KPut Options Held
8.7K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$929,6870.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$894,4850.05% of portfolio
-
Jones Financial Companies Lllp428KShares$675,7660.0% of portfolio
-
Geode Capital Management, LLC Boston, MA282KShares$445,8930.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA255KShares$402,8840.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.8M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...